[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357381-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357381-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","elevation-of-eosinophil-proportion-after-pembrolizumab-increases-the-risk-of-immune-related-adverse-events-in-patients-with-bladder-cancer","Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer","","Unmet need exists for predicting immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors. This multicenter retrospective cohort evaluated eosinophils in 124 patients with metastatic urothelial carcinoma receiving pembrolizumab between January 2018 and October 2024. Eosinophil proportion variation from baseline to 3 weeks was higher in the irAE group than the non-irAE group. In bladder cancer, an eosinophil proportion ≥5.0% identified any-grade irAEs, increasing risk by odds ratio 3.61 (95% CI 1.00-13.0).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/elevation-of-eosinophil-proportion-after-pembrolizumab-increases-the-risk-of-immune-related-adverse-events-in-patients-with-bladder-cancer/357381/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/elevation-of-eosinophil-proportion-after-pembrolizumab-increases-the-risk-of-immune-related-adverse-events-in-patients-with-bladder-cancer/357381.png","ImageObject",300,407,{"name":42,"@type":43},"Bulrr","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study question does this research address?","Question",{"text":63,"@type":64},"Whether eosinophils can predict immune-related adverse events (irAEs) in metastatic urothelial carcinoma patients treated with pembrolizumab.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients grouped in the study?",{"text":68,"@type":64},"Patients were divided into an irAE group and a non-irAE group based on whether they experienced an irAE.",{"name":70,"@type":61,"acceptedAnswer":71},"What eosinophil cutoff was associated with irAEs in bladder cancer?",{"text":72,"@type":64},"For bladder cancer, an optimal cutoff of eosinophil proportion was 5.0%, and levels ≥5.0% increased the risk of any-grade irAEs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357381,1790854171,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer\u003Cbr>Kunihiro Odagiri1 | Yoshihiko Tasaki1 | Taku Naiki2,3  | Toshiharu Morikawa2  | Keitaro Iida2 | Yusuke Noda4 | Rika Banno5 | Teruki Isobe2 | Nobuhiko Shimizu2 | Maria Aoki2,3 | Yoshihisa Mimura1  | Yosuke Sugiyama1  | Takashi Nagai2 | Toshiki Etani2 | Shuzo Hamamoto2 | Ryosuke Ando2 | Noriyasu Kawai2  |\u003Cbr>Yoko Furukawa-Hibi1  | Takahiro Yasui2\u003Cbr>1Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan | 2Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan | 3Department of Urology, Nagoya City University West Medical Center,\u003Cbr>Nagoya, Japan | 4Department of Urology, Anjo Kosei Hospital, Anjo, Japan | 5Department of Urology, Konan Kosei Hospital, Konan, Japan Correspondence: Taku Naiki ([naiki@med.nagoya-cu.ac.jp](naiki@med.nagoya-cu.ac.jp))\u003Cbr>Received: 26 June 2025 | Revised: 15 June 2026 | Accepted: 19 June 2026\u003Cbr>Keywords: bladder cancer | eosinophil | immune-related adverse event | pembrolizumab | urothelial carcinoma |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>There is an unmet need to predict immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors. This study aimed to examine whether eosinophils can predict irAEs in metastatic urothelial carcinoma (mUC) . In this multicenter cohort study, we retrospectively examined eosinophil before (baseline sample) and 3 weeks after treatment (3-week sample) in 124 patients with mUC treated with pembrolizumab between January 2018 and October 2024. We divided the patients into two groups depending on whether they had experienced an irAE (irAE group) or not (non-irAE group) . The variation ineosinophil proportion from baseline to 3 weeks was significantly higher in the irAE group than in the non-irAE group (non-irAE, 2.4%–3.1%; irAE, 2.2%–4.3%; p \u003C 0.05) . Notably, the variation in eosinophils from baseline to 3 weeks in patients with bladder cancer was significantly higher in the irAE group than in the non-irAE group (non-irAE, 2.5%–2.8%; irAE, 1.9%–4.1%; p \u003C 0.05), but not in upper urinary tract urothelial cancer (non-irAE, 2.2%–3.7%; irAE, 2.8%–4.4%; p = 0.97) . The optimal cutoff value for eosinophils in patients with bladder cancer against the occurrence of any-grade irAEs was 5.0%(area under the curve = 0.655) . Multivariable analyses showed that eosinophil levels ≥5.0% increased the risk of any-grade irAEs in patients with bladder cancer (odds ratio 3.61, 95% confidence interval, 1.00–13.0). An eosinophil proportion ≥5.0% may be an effective biomarker for evaluating pembrolizumab-induced irAEs in patients with mUC, particularly those with bladder cancer. |  |\n| 1 | Introduction | pembrolizumab has markedly changed the treatment strategies and improved the prognosis of patients with mUC [3, 4] . |\n| Metastatic urothelial carcinoma (mUC) has a poor prognosis and | For instance, the KEYNOTE-045 study demonstrated that OS |\n| a 5-year survival rate of approximately 8%[1] . To date, mainly | in patients who received pembrolizumab was significantly |\n| platinum-based chemotherapy has been used for mUC; however, the overall survival (OS) of patients receiving platinum- | longer than that in the chemotherapy group (median OS, 10.3 and 7.4 months, respectively) [3] . Additionally, the EV-302 trial |\n| based chemotherapy is approximately 1 year [2] . In this context, | demonstrated that OS in patients who received pembrolizumab |\n| Kunihiro Odagiri and Yoshihiko Tasaki contributed equally to this study. |  |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or","cbCaistADtlroiOD","https://ap.wps.com/l/cbCaistADtlroiOD","pdf",544706,"English","# Introduction\n# Materials and Methods\n## Patients and Treatment","[{\"question\":\"What study question does this research address?\",\"answer\":\"Whether eosinophils can predict immune-related adverse events (irAEs) in metastatic urothelial carcinoma patients treated with pembrolizumab.\"},{\"question\":\"How were patients grouped in the study?\",\"answer\":\"Patients were divided into an irAE group and a non-irAE group based on whether they experienced an irAE.\"},{\"question\":\"What eosinophil cutoff was associated with irAEs in bladder cancer?\",\"answer\":\"For bladder cancer, an optimal cutoff of eosinophil proportion was 5.0%, and levels ≥5.0% increased the risk of any-grade irAEs.\"}]","Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer | PDF",1790129869,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6ca29f6e60b709d64adb654b4c1a5e0.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a27f21d4d8bf803914e10e207e0b5aab.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ae0b80060e52450961f66e237ca6604.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/524d0fdc060dc2ef19ec4815c60fa926.webp",980,1287]